Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Malignancies
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a phase l study to examine Absorption, Distribution, Metabolism and Excretion of
TKI258. There are 2 cohorts. Cohort 1 (4 patients) will receive single radio-labeled 500mg
dose of TKI258 followed after 15 days by daily dosing of 400mg TKI258. Cohort 2 (9 patients)
will receive 400mg TKI258.